EyeGate reports PIII uveitis data; seeks partner or buyer
This article was originally published in Scrip
Executive Summary
EyeGate Pharma reported that EGP-437 (dexamethasone) administered via iontophoresis achieved the same response rate as the standard of care for patients with anterior uveitis in a Phase III clinical trial.